Related Experiment Video
Updated: Sep 26, 2026

Measuring Composition of CD95 Death-Inducing Signaling Complex and Processing of Procaspase-8 in this Complex
Published on: August 2, 2021
Signaling and transcriptional control of Fas ligand gene expression
1Centre for Thrombosis and Vascular Research, Department of Pathology, The University of New South Wales, Sydney, Australia.
Abstract:
Fas ligand (FasL), a member of the tumor necrosis factor family, initiates apoptosis by binding to its surface receptor Fas. As a consequence, there is sequential activation of caspases and the release of cytochrome c from the mitochondria, with additional caspase activation followed by cellular degradation and death. Recent studies have shed important insight into the molecular mechanisms controlling FasL gene expression at the level of transcription. Nuclear factors such as nuclear factor in activated T cells, nuclear factor-kappa B, specificity protein-1, early growth response factor, interferon regulatory factor, c-Myc and the forkhead transcriptional regulator, alone or cooperatively, activate FasL expression. These factors are often coexpressed with FasL in pathophysiologic settings including human atherosclerotic lesions. Here, we review these important advances in our understanding of the signaling and transcriptional mechanisms controlling FasL gene expression.
Insights
Fas ligand (FasL) triggers apoptosis by activating caspases. Nuclear factors regulate FasL gene expression transcriptionally, impacting cellular degradation and death, particularly in diseases like atherosclerosis.
Area of Science:
- Molecular Biology
- Immunology
- Cellular Biology
Background:
- Fas ligand (FasL), a tumor necrosis factor family member, initiates apoptosis through Fas receptor binding.
- Apoptosis involves sequential caspase activation, mitochondrial cytochrome c release, and cellular degradation.
- Understanding FasL's role is crucial in diseases involving programmed cell death.
Purpose of the Study:
- To review recent advances in understanding the molecular mechanisms controlling FasL gene expression.
- To elucidate the transcriptional regulation of FasL.
- To highlight the role of nuclear factors in FasL expression.
Main Methods:
- Review of existing literature on FasL gene expression and regulation.
- Analysis of studies identifying nuclear factors involved in FasL transcription.
- Examination of the coexpression of FasL and regulatory factors in pathophysiological settings.
Main Results:
- Multiple nuclear factors, including NFAT, NF-κB, Sp1, EGR, IRF, c-Myc, and FOX, activate FasL expression.
- These factors can act alone or cooperatively to modulate FasL transcription.
- Coexpression of these factors with FasL is observed in disease states such as human atherosclerotic lesions.
Conclusions:
- FasL gene expression is tightly controlled at the transcriptional level by a network of nuclear factors.
- These regulatory mechanisms are relevant to pathophysiological conditions, including atherosclerosis.
- Further research into these signaling and transcriptional pathways is warranted.
Related Concept Videos
The Extrinsic Apoptotic Pathway
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
The JAK-STAT Signaling Pathway
TGF - β Signaling Pathway
Intracellular Signaling Affects Focal Adhesions
Some...
Amplifying Signals via Enzymatic Cascade

